Human epidermal growth factor receptor-2 (HER2) is overexpressed in ~25–30% of breast cancers, but also in other malignancies including gastric cancer, head and neck cancer, and ovarian cancer1–5. This evidence concerns the gene ERBB2 and gastric cancer.